ArticleFrontiers in pharmacology2025
Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The COMPASSION-15 trial confirmed the safety and effectiveness of cadonilimab, a bispecific antibody targeting both programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4), in treating human epidermal growth factor receptor 2 (HER2) negative advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Notably, it demonstrated significant survival benefits even in the low programmed death ligand 1 (PD-L1) expression subgroup, overcoming the limitations of current immunotherapy. This study aims to comprehensively evaluate its cost-effectiveness. Methods: The cost-effectiveness of cadonilimab plus chemotherapy compared to chemotherapy alone was evaluated using a partitioned survival model with a 10-year time horizon, based on data from the COMPASSION-15 trial. Incremental cost-effectiveness ratio (ICER) was estimated to ascertain the cost-effectiveness. Furthermore, subgroup analysis stratified by PD-L1 combined positive score (CPS) thresholds, as well as sensitivity and scenario analyses, were performed. Results: The estimated ICER value was $35,613.34/quality-adjusted life-year (QALY) for the entire cohort, $21,142.58/QALY for the high PD-L1 expression subgroup (CPS ≥5), and $45,000.62/QALY for the low PD-L1 expression subgroup (CPS <5). Only the high PD-L1 expression subgroup achieved the cost-effectiveness, as its ICER value was below the willingness-to-pay (WTP) threshold of $24,600/QALY. Sensitivity and scenario analyses demonstrated the robustness of the result. Conclusion: In China, incorporating cadonilimab with chemotherapy was found to be more cost-effective as a first-line treatment for HER2-negative advanced G/GEJA in the PD-L1 CPS ≥5 subgroup. Nevertheless, it was not cost-effective for either the entire cohort or the PD-L1 CPS <5 subgroup. These findings can provide valuable insights for future pricing strategies and healthcare decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.